Literature DB >> 16474094

Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection.

David Alonso1, Jose Muñoz, Joaquim Gascón, Maria Eugenia Valls, Manuel Corachan.   

Abstract

A single 40 mg/kg dose of praziquantel (PZQ) continues to be the standard treatment for schistosomiasis caused by S. mansoni and S. haematobium in all clinical settings. Experimental development of drug resistance and the recent isolation of S. mansoni strains with a natural tolerance to high doses of PZQ have raised concerns over the adequacy of such a dose. We describe two Spanish travelers with genitourinary schistosomiasis caused by S. haematobium in whom repeated standard treatment failed to clear the infection.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16474094

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN： 0002-9637            Impact factor:   2.345


  49 in total

Review 1.  Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance.

Authors:  Nuno Vale; Maria João Gouveia; Gabriel Rinaldi; Paul J Brindley; Fátima Gärtner; José M Correia da Costa
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Change of semen quality after foreign travel: a rare presentation of genital schistosomiasis.

Authors:  Amr Hawary; Richard Taylor; Anne McEwans; Richard Napier-Hemy
Journal:  Int Urol Nephrol       Date:  2010-08-03       Impact factor: 2.370

3.  In-vivo activity of dihydroartemisinin against Schistosoma japonicum.

Authors:  H-J Li; W Wang; G-L Qu; Y-H Tao; Y-T Xing; Y-Z Li; J-Y Wei; J-R Dai; Y-S Liang
Journal:  Ann Trop Med Parasitol       Date:  2011-03

4.  Dihydroartemisinin-praziquantel combinations and multiple doses of dihydroartemisinin in the treatment of Schistosoma japonicum in experimentally infected mice.

Authors:  H-J Li; W Wang; Y-H Tao; G-L Qu; Y-T Xing; Y-Z Li; J-Y Wei; J-R Dai; Y-S Liang
Journal:  Ann Trop Med Parasitol       Date:  2011-06

5.  In vitro activities of trioxaquines against Schistosoma mansoni.

Authors:  Jérôme Boissier; Frédéric Coslédan; Anne Robert; Bernard Meunier
Journal:  Antimicrob Agents Chemother       Date:  2009-07-13       Impact factor: 5.191

6.  Molecular cloning and characterization of Schistosoma japonicum aldose reductase.

Authors:  Jian Liu; Jipeng Wang; Shuqi Wang; Bin Xu; Xiufeng Liu; Xiaoning Wang; Wei Hu
Journal:  Parasitol Res       Date:  2012-11-17       Impact factor: 2.289

7.  Efficacy of artemether and artesunate in mice infected with praziquantel non-susceptible isolate of Schistosoma japonicum.

Authors:  Wei Wang; Tian-Yu Li; Yuan Ji; Guo-Li Qu; Yi-Li Qian; Hong-Jun Li; Jian-Rong Dai; You-Sheng Liang
Journal:  Parasitol Res       Date:  2013-12-11       Impact factor: 2.289

8.  Design and synthesis of molecular probes for the determination of the target of the anthelmintic drug praziquantel.

Authors:  Lalit Kumar Sharma; Pauline M Cupit; Tino Goronga; Thomas R Webb; Charles Cunningham
Journal:  Bioorg Med Chem Lett       Date:  2014-04-13       Impact factor: 2.823

Review 9.  The role of evolutionary biology in research and control of liver flukes in Southeast Asia.

Authors:  Pierre Echaubard; Banchob Sripa; Frank F Mallory; Bruce A Wilcox
Journal:  Infect Genet Evol       Date:  2016-05-16       Impact factor: 3.342

10.  Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni.

Authors:  Sandra D Melman; Michelle L Steinauer; Charles Cunningham; Laura S Kubatko; Ibrahim N Mwangi; Nirvana Barker Wynn; Martin W Mutuku; Diana M S Karanja; Daniel G Colley; Carla L Black; William Evan Secor; Gerald M Mkoji; Eric S Loker
Journal:  PLoS Negl Trop Dis       Date:  2009-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.